nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2014 | Editorial Commentary

Cost-effectiveness of ^99mTc-MIBI in the evaluation of thyroid nodules for malignancy: a new lease of life for an old radiopharmaceutical?

verfasst von: Frederik A. Verburg, Florian F. Behrendt, Felix M. Mottaghy, Alexander Heinzel

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

In nuclear medicine practice, physicians are often confronted with the problem that formal registration of a specific radiopharmaceutical and the indications for its use are lacking (e.g. the modern ⁶⁸Ga-labelled somatostatin analogues). If formal registration is available, this registration often only covers a few, specific and predominantly commercially interesting indications even when the radiopharmaceutical can be applied more broadly. A good example of the latter is the case of ^99mTc-methoxyisobutylisonitrile (MIBI). …

Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation. 1988;77:491–8.PubMedCrossRef

Stirner H, Buell U, Kleinhans E, Bares R, Grosse W. Myocardial kinetics of 99Tcm hexakis-(2-methoxy-isobutyl-isonitrile) (HMIBI) in patients with coronary heart disease: a comparative study versus 201Tl with SPECT. Nucl Med Commun. 1988;9:15–23.PubMedCrossRef

Committee for Medicinal Products for Human Use. Guideline on core Summary of Products Characteristics and package leaflet for technetium (99mTc) sestamibi. London: European Medicines Agency, 2012.

Foldes I, Levay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med. 1993;20:330–3.PubMedCrossRef

Sundram FX, Mack P. Evaluation of thyroid nodules for malignancy using 99Tcm-sestamibi. Nucl Med Commun. 1995;16:687–93.PubMedCrossRef

Kresnik E, Gallowitsch HJ, Mikosch P, Gomez I, Lind P. Technetium-99m-MIBI scintigraphy of thyroid nodules in an endemic goiter area. J Nucl Med. 1997;38:62–5.PubMed

Mezosi E, Bajnok L, Gyory F, Varga J, Sztojka I, Szabo J, et al. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules. Eur J Nucl Med. 1999;26:798–803.PubMedCrossRef

Sathekge MM, Mageza RB, Muthuphei MN, Modiba MC, Clauss RC. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head Neck. 2001;23:305–10.PubMedCrossRef

Demirel K, Kapucu O, Yucel C, Ozdemir H, Ayvaz G, Taneri F. A comparison of radionuclide thyroid angiography, (99m)Tc-MIBI scintigraphy and power Doppler ultrasonography in the differential diagnosis of solitary cold thyroid nodules. Eur J Nucl Med Mol Imaging. 2003;30:642–50.PubMedCrossRef

10.

Hurtado-Lopez LM, Arellano-Montano S, Torres-Acosta EM, Zaldivar-Ramirez FR, Duarte-Torres RM, Alonso-De-Ruiz P, et al. Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule. Eur J Nucl Med Mol Imaging. 2004;31:1273–9.PubMedCrossRef

11.

Theissen P, Schmidt M, Ivanova T, Dietlein M, Schicha H. MIBI scintigraphy in hypofunctioning thyroid nodules – can it predict the dignity of the lesion? Nuklearmedizin. 2009;48:144–52.PubMed

12.

Giovanella L, Suriano S, Maffioli M, Ceriani L, Spriano G. (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck. 2010;32:607–11.PubMed

13.

Wale A, Miles K, Young B, Zammit C, Williams A, Quin J, et al. Combined 99m-Tc-methoxyisobutylisonitrile scintigraphy and fine needle aspiration cytology offers an accurate and potentially cost effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2546-0.PubMed

14.

Treglia G, Caldarella C, Saggiorato E, Ceriani L, Orlandi F, Salvatori M, et al. Diagnostic performance of (99m)Tc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. Endocrine. 2013;44:70–8.PubMedCrossRef

15.

Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol ). 2012;24:159–61.CrossRef

16.

Heinzel A, Stock S, Langen KJ, Muller D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. J Nucl Med. 2012;53:552–8.PubMedCrossRef

17.

Heinzel A, Stock S, Langen KJ, Muller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging. 2012;39:1089–96.PubMedCrossRef

18.

Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol. 2006;155:405–14.PubMedCrossRef

Titel: Cost-effectiveness of 99mTc-MIBI in the evaluation of thyroid nodules for malignancy: a new lease of life for an old radiopharmaceutical?
verfasst von: Frederik A. Verburg
Florian F. Behrendt
Felix M. Mottaghy
Alexander Heinzel
Publikationsdatum: 01.01.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2583-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cost-effectiveness of ^99mTc-MIBI in the evaluation of thyroid nodules for malignancy: a new lease of life for an old radiopharmaceutical?

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Quantitative myocardial blood flow imaging: not all flow is equal

Heinrich Iro, Alessandro Bozzato and Johannes Zenk (Eds): Atlas of Head and Neck Ultrasound

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.

Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients

11C-Acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment

Towards an optimal semiquantitative approach in giant cell arteritis: an 18F-FDG PET/CT case-control study